Definium Therapeutics Stock Soars After Anxiety Drug Succeeds in Phase 3 Trial

Definium Therapeutics (DFTX) stock surged 20.7% in pre-open trading on Monday after the company reported positive top-line results from a pivotal Phase 3 trial for its lead drug candidate, DT120 ODT, in adults with generalized anxiety disorder (GAD).

Panorama Trial Meets Primary Endpoint

The company announced that its Phase 3 Panorama study met its primary endpoint. The trial evaluated DT120 ODT, a single-dose orally disintegrating tablet of lysergide (LSD), for the treatment of GAD.

According to the release, the drug demonstrated a highly statistically significant result, delivering a placebo-adjusted reduction of 5.1 points on the Hamilton Anxiety Rating Scale (HAM-A) at Week 12. The trial also showed a strong effect size of 0.64. Trading in the company's stock was halted pending the news release, with a webcast scheduled for 8:00 a.m. EDT to discuss the data.

Market Impact and Context

Ad

The strong clinical data fueled a sharp rally in the company's shares, a move that stood in stark contrast to the broader market. The rally occurred as the S&P 500 fell 0.6% and the NASDAQ Composite declined 1.4%, underscoring that the gains were driven entirely by the company-specific news. The stock is now approaching its 52-week high of $49.70.

Building a Case for Regulatory Submission

This is the second positive Phase 3 readout for DT120 in GAD, following the success of the earlier Voyage study. The consistent results strengthen the drug's profile as the company prepares for potential regulatory filings.

The news follows another significant milestone for Definium Therapeutics. Earlier this month, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for DT120 for the treatment of major depressive disorder (MDD). With strong analyst support already in place, investors will now be focused on the company's timeline for submitting the drug for FDA approval for both GAD and MDD.